ABBV vs TARS: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

ABBV is the larger of the two ($509.92B market cap): the incumbent the market prices for continued execution (17.79x forward earnings, beta 0.19). TARS is the smaller challenger ($3.68B), actually pricier on forward earnings (346.91x): more room to run, but more to prove. If you believe in growth, TARS fits: analysts expect its revenue to rise 27% next year, against 9% for ABBV. If you believe in paying less for profit, ABBV fits: it trades at 17.79x forward earnings, against 346.91x for TARS.

ABBV vs TARS: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricABBVTARSWhat it tells you
Market cap$509.92B$3.68BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E17.79346.91Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.190.33Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range87% of range55% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Reading it: ABBV is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how ABBV and TARS affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABBV and TARS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABBV and TARS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does AbbVie (ABBV) do?

AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. It focuses on discovering and commercializing medicines for immunology, oncology, neuroscience, and aesthetics. Its immunology franchise anchors the business: historically through Humira (adalimumab), and increasingly through Skyrizi (risankizumab) and Rinvoq (upadacitinib), which treat conditions such as plaque psoriasis, Crohn's disease, rheumatoid arthritis, and ulcerative colitis. Oncology contributes through Imbruvica (developed in collaboration with Johnson and Johnson) and Venclexta (in collaboration with Roche), while the 2020 acquisition of Allergan added Botox Therapeutic, Vraylar, and the aesthetics portfolio including Botox Cosmetic and Juvederm. Revenue is generated by selling branded pharmaceuticals at negotiated prices to wholesale distributors, specialty pharmacies, and health systems across more than 175 countries.

Full ABBV guide

What does Tarsus Pharmaceuticals (TARS) do?

Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on therapeutic eye care. Its business is anchored by XDEMVY (lotilaner ophthalmic solution 0.25%), the first and only FDA-approved treatment that directly targets the Demodex mites behind Demodex blepharitis, a common and previously under-treated eyelid condition. The company delivered roughly 400,000 bottles of XDEMVY in 2025 (up from about 163,000 in 2024) and is building a lotilaner-based pipeline that includes TP-04 for ocular rosacea and TP-05 for potential prevention of Lyme disease, with topline data for both expected in the first half of 2027. In September 2026 Tarsus completed its acquisition of privately held Alkeus Pharmaceuticals, whose lead asset, gildeuretinol acetate (ALK-001), is an oral drug in a global Phase 3 trial (NORTHSTAR) for Stargardt disease, an inherited retinal disease with no FDA-approved therapy; topline data is expected in 2029, and the deal terms were not disclosed in the closing announcement.

Full TARS guide

ABBV vs TARS: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • ABBV drivers: Skyrizi and Rinvoq replacing Humira faster than expected; Neuroscience becoming a meaningful second growth engine.
  • TARS drivers: XDEMVY prescription growth; Large, under-penetrated indication.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. For TARS, the overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company.

ABBV or TARS: which should you pick?

If the story you believe is ABBV's (Skyrizi and Rinvoq replacing Humira faster than expected), ABBV is the more direct way to own it; if it is TARS's (XDEMVY prescription growth), TARS is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABBV and TARS guides.

ABBV vs TARS: the full fundamentals

ABBV. The gap between the trailing GAAP P/E (about 50x, inflated by non-cash acquired IPR and D charges on recent deals) and the forward P/E of roughly 17.8x illustrates why analysts and management prefer adjusted metrics: upfront licensing and milestone payments depress reported earnings without reducing cash generation. The trailing multiple has fallen from about 80x in October as a strong Q3 GAAP quarter (about $4.2 billion of net income) replaced weaker ones, while the forward multiple has drifted up with the share price. The 26 covering analysts have a buy consensus and a mean target near $316.

TARS. As of November 20, 2026 TARS traded near $74.50 with a market capitalization around $3.7 billion, roughly 5.4x trailing revenue. Trailing earnings are swamped by the one-time acquired R&D charges, so sales growth, gross margin and free cash flow are the more usable anchors, and the forward P/E (about 350x on 2027 consensus EPS of $0.22) mainly shows how thin expected profit still is. The nine analysts in Yahoo Finance's sample carry a mean target near $103.44.

Headline figures (approximate, November 2026): ABBV shows revenue (ttm) ~$66.0 billion (Q3 2026 ~$17.4B, up ~10% YoY), adjusted eps Q3 2026 $3.82 vs $3.76 estimate; FY2026 consensus ~$13.98; FY2027 consensus ~$16.22, gaap net income (ttm) ~$10.3 billion (GAAP EPS ~$5.82, depressed by acquired IPR and D), margins (ttm) ~74% gross, ~37% operating, ~16% net; TARS shows revenue (ttm) ~$682M, q3 2026 xdemvy net sales ~$195M (+~64% YoY), q3 2026 net loss ~($668M) incl. ~$632M acquired IPR&D; ($0.87)/sh vs ~($1.77) est., 2026 xdemvy guidance $715M to $730M (raised Nov 3).

The bottom line: ABBV vs TARS

ABBV and TARS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ABBV and TARS exposure against your real portfolio. It is not an investment adviser.

Wondering how ABBV or TARS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about AbbVie

Ask Walnut's AI anything about ABBV and see how it fits what you own.

FAQ

What is the difference between ABBV and TARS?

+

AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on therapeutic eye care. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ABBV or TARS the better stock?

+

Neither is universally better. ABBV is the larger incumbent; TARS is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ABBV or TARS?

+

On forward P/E (as of November 2026), ABBV trades at 17.79x and TARS at 346.91x, so ABBV is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ABBV and TARS?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ABBV vs TARS?

+

ABBV: The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. AbbVie also carries a heavy debt load, about $81.3 billion as of September 2026 against about $10.8 billion of cash, a legacy of the Allergan acquisition, constraining financial flexibility if credit markets tighten or a major pipeline bet fails. GAAP earnings are depressed by acquired research charges, so the dividend exceeds trailing GAAP net income (a payout ratio near 117% of trailing GAAP EPS of about $5.82), and it is covered by cash flow rather than reported profit. Integrating acquisitions such as Apogee Therapeutics introduces execution risk, the aesthetics segment (Botox Cosmetic, Juvederm) has shown sensitivity to consumer spending cycles, and after a 26% gain in 2026 the shares trade near their highs, though the mean analyst target has risen to about $316. TARS: The overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company. In late June 2026, short-seller Culper Research alleged that XDEMVY sales depend on donations routed to a blepharitis copay fund in a way it argues may violate the federal Anti-Kickback Statute, and it claimed the true addressable market is roughly a fifth of company estimates; these are unproven allegations, but they introduce regulatory, reimbursement, and reputational uncertainty. Tarsus also depends on intellectual property licensed from Elanco, faces gross-to-net and Medicare Part D dynamics that can compress net pricing, and still runs near breakeven with a history of losses. Cheaper off-label alternatives and potential future competitors, plus binary Phase 2 pipeline readouts, round out the risk set. The Alkeus and Irenix purchases add integration and clinical risk in new therapeutic areas, already cost about $632 million in acquired R&D charges in the third quarter, and bring trial costs that will weigh on reported earnings for years; cash fell to about $310 million at the end of September. Insider share sales in September 2026 and a second-quarter EPS miss also weighed on sentiment before the third-quarter beat.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ABBV or TARS; figures are approximate and dated (as of November 2026). Verify current data before investing.